THANK YOU FOR SUBSCRIBING
Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
The BD UltraSafePlus 2.25 mL’s innovative design compliments biopharmaceutical firms’ combination product strategy, allowing patients to inject complicated, high-viscosity medications under their own control.
FREMONT, CA: Patients or caregivers frequently self-administer biologic medicines, necessitating delivery systems that are simple to use and safe to use in non-clinical settings. However, biologics’ viscosity and injection volume have been increasing in recent years (>1 mL, >10 cP), exceeding the capabilities of several current injectable drug delivery devices. Injecting biologic formulations with high volumes and viscosities frequently necessitates greater power, which can be difficult for users.
BD (Becton, Dickinson and Company), a leading global medical technology company, rolled out the BD UltraSafePlus 2.25 mL Passive Needle Guard for use by pharmaceutical companies in drug-device combination products. The BD UltraSafePlus 2.25 mL system, when used with a Glass Prefillable Syringe, allows for subcutaneous delivery of biologic solutions with fill volumes up to 2 mL and viscosities up to 30 cP.
The BD UltraSafePlus 2.25 mL is the newest addition to BD’s line of drug delivery systems for combination products, and it is designed to satisfy the demands of healthcare practitioners, patients, and carers performing manual biologic injections. The BD UltraSafePlus 2.25 mL’s innovative design compliments biopharmaceutical firms’ combination product strategy, allowing patients to inject complicated, high-viscosity medications under their own control.
“With BD UltraSafe Plus 2.25 mL, we are innovating drug delivery systems with a goal to provide confidence and ease of use to patients and improve their self-injection experience, and to serve the expanding biologic drug delivery design space,” said Eric Borin, Worldwide President, BD Medical Pharmaceutical Systems. “We are excited to support bio-pharmaceutical drug launches with a new and robust platform technology that is compatible with BD Neopak 2.25 mL Glass Prefillable Syringe and supports our customers high-speed assembly by leveraging extensive experience with BD UltraSafe Passive Needle Guard in commercialized combination products.”
The usability of the BD UltraSafePlus 2.25 mL was proved in human factors validation research. The majority of participants expressed trust that the activated safety mechanism would protect them from needlestick injuries.
The BD Neopak Glass Prefillable Syringe, BD NeopakXtraFlow Glass Prefillable Syringe, BD Intevia Disposable Autoinjector, and BD UltraSafePlus Passive Needle Guard are among the innovative options being developed by BD for biopharmaceutical companies looking to deliver biologics in 2 mL dose volumes. Biopharmaceutical companies can now use the BD UltraSafePlus 2.25 mL Passive Needle Guard to develop new products.
Read Also
